Summit Therapeutics Stock Skyrockets After Cancer Drug Outperforms Keytruda
TL;DR
Summit Therapeutics Inc. shares soared 272% after a late-stage trial showed their cancer drug ivonescimab significantly outperformed Merck's Keytruda in treating non-small cell lung cancer, leading to a decline in Merck's shares. The trial, conducted in China, demonstrated a meaningful improvement in progression-free survival, with analysts optimistic about the drug's potential in other populations and across multiple solid tumors.
Topics:businessbusinesshealth#businesshealth#cancer-drug#ivonescimab#merck#stock-surge#summit-therapeutics
- Summit Shares Soar After Cancer Drug Tops Merck's Keytruda Yahoo Finance
- Why Summit Therapeutics Stock Is Sinking Today Yahoo Finance
- Pharma Billionaire's Fortune More Than Doubles In A Day On Cancer Drug Trial News Forbes
- Summit Therapeutics (SMMT): Ivonescimab Beats Pembrolizumab Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC StreetInsider.com
- Summit stock gains as lead asset beats Keytruda (NASDAQ:SMMT) Seeking Alpha
Want the full story? Read the original reporting
Read on Yahoo Finance